CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Pfizer INC (PFE) / tucatinib
Forward catalyst · PFE

tucatinib

Sponsor Pfizer INC · listed as PFE

READOUT Phase 3 Confidence: medium Source: clinicaltrials

tucatinib is a clinical-stage drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 31, 2027 (day precision, medium confidence), tied to trial NCT05253651. The asset is in Phase 3 and currently recruiting, studied in Colorectal Neoplasms. It appears across 5 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2027-12-31
As disclosedDec 31, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05253651
PhasePHASE3
StatusRECRUITING
Lead sponsorSeagen, a wholly owned subsidiary of Pfizer
Listed asPFE
Condition(s)Colorectal Neoplasms
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More PFE catalysts

Related catalysts and sponsor